http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 05 Aug 2026 16:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26874542.html si-local-file:///var/storage/secattach/20260805/26874542.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26874542.html Wed, 05 Aug 2026 16:15:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26874542.html si-local-file:///var/storage/secattach/20260805/26874542.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26874542.html Wed, 05 Aug 2026 16:15:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26874542.html si-local-file:///var/storage/secattach/20260805/26874542.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26874542.html Wed, 05 Aug 2026 16:15:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26874542.html si-local-file:///var/storage/secattach/20260805/26874542.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++CITIUS+ONCOLOGY%2C+INC.++++++++++++++++/26874542.html Wed, 05 Aug 2026 16:15:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+05/26871493.html si-local-file:///var/storage/secattach/20260805/26871493.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+05/26871493.html Wed, 05 Aug 2026 09:29:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+05/26871493.html si-local-file:///var/storage/secattach/20260805/26871493.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+05/26871493.html Wed, 05 Aug 2026 09:29:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+05/26871493.html si-local-file:///var/storage/secattach/20260805/26871493.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+05/26871493.html Wed, 05 Aug 2026 09:29:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+05/26871493.html si-local-file:///var/storage/secattach/20260805/26871493.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Aug+05/26871493.html Wed, 05 Aug 2026 09:29:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Citius+Pharmaceuticals%2C+++For%3A+Aug+05/26871470.html si-local-file:///var/storage/secattach/20260805/26871470.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Citius+Pharmaceuticals%2C+++For%3A+Aug+05/26871470.html Wed, 05 Aug 2026 09:27:00 -0400 CTXR O.11391251 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Citius+Pharmaceuticals%2C+++For%3A+Aug+05/26871470.html si-local-file:///var/storage/secattach/20260805/26871470.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Citius+Pharmaceuticals%2C+++For%3A+Aug+05/26871470.html Wed, 05 Aug 2026 09:27:00 -0400 CTXR O.11391251 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html <div class="xn-content"> <p class="prntac"><i>New institutional accounts ordering LYMPHIR increased 78% quarter over quarter</i></p><p class="prntac">LYMPHIR's near-universal payer coverage expands market access</p><p class="prntac">Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds <money>$400 million</money></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR^® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority <location value="LC/us" idsrc="xmltag.org" >U.S</location>. treatment centers, and http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html Wed, 05 Aug 2026 09:17:00 -0400 A.06822034 CTOR CTXR O.11391251 O.20026344 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html <div class="xn-content"> <p class="prntac"><i>New institutional accounts ordering LYMPHIR increased 78% quarter over quarter</i></p><p class="prntac">LYMPHIR's near-universal payer coverage expands market access</p><p class="prntac">Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds <money>$400 million</money></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR^® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority <location value="LC/us" idsrc="xmltag.org" >U.S</location>. treatment centers, and http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html Wed, 05 Aug 2026 09:17:00 -0400 A.06822034 CTOR CTXR O.11391251 O.20026344 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html <div class="xn-content"> <p class="prntac"><i>New institutional accounts ordering LYMPHIR increased 78% quarter over quarter</i></p><p class="prntac">LYMPHIR's near-universal payer coverage expands market access</p><p class="prntac">Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds <money>$400 million</money></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR^® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority <location value="LC/us" idsrc="xmltag.org" >U.S</location>. treatment centers, and http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html Wed, 05 Aug 2026 09:17:00 -0400 A.06822034 CTOR CTXR O.11391251 O.20026344 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html <div class="xn-content"> <p class="prntac"><i>New institutional accounts ordering LYMPHIR increased 78% quarter over quarter</i></p><p class="prntac">LYMPHIR's near-universal payer coverage expands market access</p><p class="prntac">Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds <money>$400 million</money></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR^® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority <location value="LC/us" idsrc="xmltag.org" >U.S</location>. treatment centers, and http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html Wed, 05 Aug 2026 09:17:00 -0400 A.06822034 CTOR CTXR O.11391251 O.20026344 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html <div class="xn-content"> <p class="prntac"><i>New institutional accounts ordering LYMPHIR increased 78% quarter over quarter</i></p><p class="prntac">LYMPHIR's near-universal payer coverage expands market access</p><p class="prntac">Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds <money>$400 million</money></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR^® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority <location value="LC/us" idsrc="xmltag.org" >U.S</location>. treatment centers, and http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html Wed, 05 Aug 2026 09:17:00 -0400 A.06822034 CTOR CTXR O.11391251 O.20026344 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html <div class="xn-content"> <p class="prntac"><i>New institutional accounts ordering LYMPHIR increased 78% quarter over quarter</i></p><p class="prntac">LYMPHIR's near-universal payer coverage expands market access</p><p class="prntac">Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds <money>$400 million</money></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR^® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority <location value="LC/us" idsrc="xmltag.org" >U.S</location>. treatment centers, and http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html Wed, 05 Aug 2026 09:17:00 -0400 A.06822034 CTOR CTXR O.11391251 O.20026344 O.54377330 http://www.streetinsider.com/PRNewswire/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html <div class="xn-content"> <p class="prntac"><i>New institutional accounts ordering LYMPHIR increased 78% quarter over quarter</i></p><p class="prntac">LYMPHIR's near-universal payer coverage expands market access</p><p class="prntac">Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds <money>$400 million</money></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR^® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority <location value="LC/us" idsrc="xmltag.org" >U.S</location>. treatment centers, and http://www.streetinsider.com/PRNewswire/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html Wed, 05 Aug 2026 09:17:00 -0400 A.06822034 CTOR CTXR O.11391251 O.20026344 O.54377330 http://www.streetinsider.com/PRNewswire/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html <div class="xn-content"> <p class="prntac"><i>New institutional accounts ordering LYMPHIR increased 78% quarter over quarter</i></p><p class="prntac">LYMPHIR's near-universal payer coverage expands market access</p><p class="prntac">Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds <money>$400 million</money></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR^® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority <location value="LC/us" idsrc="xmltag.org" >U.S</location>. treatment centers, and http://www.streetinsider.com/PRNewswire/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html Wed, 05 Aug 2026 09:17:00 -0400 A.06822034 CTOR CTXR O.11391251 O.20026344 O.54377330 http://www.streetinsider.com/PRNewswire/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html <div class="xn-content"> <p class="prntac"><i>New institutional accounts ordering LYMPHIR increased 78% quarter over quarter</i></p><p class="prntac">LYMPHIR's near-universal payer coverage expands market access</p><p class="prntac">Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds <money>$400 million</money></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR^® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority <location value="LC/us" idsrc="xmltag.org" >U.S</location>. treatment centers, and http://www.streetinsider.com/PRNewswire/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html Wed, 05 Aug 2026 09:17:00 -0400 A.06822034 CTOR CTXR O.11391251 O.20026344 O.54377330 http://www.streetinsider.com/PRNewswire/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html <div class="xn-content"> <p class="prntac"><i>New institutional accounts ordering LYMPHIR increased 78% quarter over quarter</i></p><p class="prntac">LYMPHIR's near-universal payer coverage expands market access</p><p class="prntac">Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds <money>$400 million</money></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR^® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority <location value="LC/us" idsrc="xmltag.org" >U.S</location>. treatment centers, and http://www.streetinsider.com/PRNewswire/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html Wed, 05 Aug 2026 09:17:00 -0400 A.06822034 CTOR CTXR O.11391251 O.20026344 O.54377330 http://www.streetinsider.com/PRNewswire/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html <div class="xn-content"> <p class="prntac"><i>New institutional accounts ordering LYMPHIR increased 78% quarter over quarter</i></p><p class="prntac">LYMPHIR's near-universal payer coverage expands market access</p><p class="prntac">Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds <money>$400 million</money></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR^® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority <location value="LC/us" idsrc="xmltag.org" >U.S</location>. treatment centers, and http://www.streetinsider.com/PRNewswire/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html Wed, 05 Aug 2026 09:17:00 -0400 A.06822034 CTOR CTXR O.11391251 O.20026344 O.54377330 http://www.streetinsider.com/PRNewswire/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html <div class="xn-content"> <p class="prntac"><i>New institutional accounts ordering LYMPHIR increased 78% quarter over quarter</i></p><p class="prntac">LYMPHIR's near-universal payer coverage expands market access</p><p class="prntac">Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds <money>$400 million</money></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR^® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority <location value="LC/us" idsrc="xmltag.org" >U.S</location>. treatment centers, and http://www.streetinsider.com/PRNewswire/Citius+Oncology+Reports+Strong+Commercial+Momentum+for+its+Cancer+Treatment/26871381.html Wed, 05 Aug 2026 09:17:00 -0400 A.06822034 CTOR CTXR O.11391251 O.20026344 O.54377330 http://www.streetinsider.com/Corporate+News/Citius+Oncology+expands+LYMPHIR+sales+force+ahead+of+August+rollout/26793478.html <p>Citius Oncology, Inc. (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), has added 21 commercial field-based professionals and eight medical science liaisons to support the U.S. launch of LYMPHIR (denileukin diftitox-cxdl), according to a press release issued July 21, 2026. All personnel are expected to be fully deployed nationwide by August 2026.</p><p>The expansion was funded through a May 2026 financing and carried out by EVERSANA, Citius Oncology's exclusive commercialization partner. EVERSANA also provides the company with medical information, pharmacovigilance, revenue cycle management, data and analytics, and patient assistance services.</p><p>The company reports growing numbers of treatment accounts placing http://www.streetinsider.com/Corporate+News/Citius+Oncology+expands+LYMPHIR+sales+force+ahead+of+August+rollout/26793478.html Tue, 21 Jul 2026 09:18:29 -0400 CTOR CTXR http://www.streetinsider.com/Corporate+News/Citius+Oncology+expands+LYMPHIR+sales+force+ahead+of+August+rollout/26793478.html <p>Citius Oncology, Inc. (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), has added 21 commercial field-based professionals and eight medical science liaisons to support the U.S. launch of LYMPHIR (denileukin diftitox-cxdl), according to a press release issued July 21, 2026. All personnel are expected to be fully deployed nationwide by August 2026.</p><p>The expansion was funded through a May 2026 financing and carried out by EVERSANA, Citius Oncology's exclusive commercialization partner. EVERSANA also provides the company with medical information, pharmacovigilance, revenue cycle management, data and analytics, and patient assistance services.</p><p>The company reports growing numbers of treatment accounts placing http://www.streetinsider.com/Corporate+News/Citius+Oncology+expands+LYMPHIR+sales+force+ahead+of+August+rollout/26793478.html Tue, 21 Jul 2026 09:18:29 -0400 CTOR CTXR http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Nationwide+Deployment+of+LYMPHIR%27s+Broadened+Commercial+Organization+and+Expanding+Market+Adoption/26793467.html <div class="xn-content"> <p class="prntac"><i>Expanded commercial and medical affairs teams expected to be fully operational throughout the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. by August </i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the commercial launch of LYMPHIR^® (denileukin diftitox-cxdl), highlighting continued progress across market access, commercial execution, and physician adoption.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Citius+Oncology+Reports+Nationwide+Deployment+of+LYMPHIR%27s+Broadened+Commercial+Organization+and+Expanding+Market+Adoption/26793467.html Tue, 21 Jul 2026 09:17:00 -0400 A.06822034 A.24478717 CTOR CTXR O.11391251 O.20026344 O.41511844 O.54377330